Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

URI professor studies rare hereditary disorder Fanconi anemia in children

URI professor studies rare hereditary disorder Fanconi anemia in children

Enhanced recovery pathway recovers patients undergoing gynecologic surgery more quickly

Enhanced recovery pathway recovers patients undergoing gynecologic surgery more quickly

Enhanced recovery pathway for patients undergoing gynecologic surgery recovers more quickly

Enhanced recovery pathway for patients undergoing gynecologic surgery recovers more quickly

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

CA-125: Screening tool to detect ovarian cancer in early stages

CA-125: Screening tool to detect ovarian cancer in early stages

Screening strategy for ovarian cancer appears to be highly specific for detecting disease at early stages

Screening strategy for ovarian cancer appears to be highly specific for detecting disease at early stages

MC1R mutation responsible for red hair phenotype also promotes cancer-causing pathway

MC1R mutation responsible for red hair phenotype also promotes cancer-causing pathway

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

Report demonstrates clinical use of novel biomarker to assess cancer progression, inflammation

Mutational signatures in DNA explain genetic development, history of cancers in patients

Mutational signatures in DNA explain genetic development, history of cancers in patients

Study shows metastasizing cancer cells undergo molecular change during EMT

Study shows metastasizing cancer cells undergo molecular change during EMT

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

Precision Therapeutics continues its support to NOCC Pittsburgh Chapter

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

NW Bio receives decision to continue Phase III clinical trial on brain cancer in Germany

Fertility medications not linked with increased risk of CVD later in life

Fertility medications not linked with increased risk of CVD later in life

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

ImmunoCellular initiates ICT-121 phase I trial in patients with recurrent glioblastoma multiforme

WHO aims to increase global rate of breastfeeding for six months to 50% by 2025

WHO aims to increase global rate of breastfeeding for six months to 50% by 2025

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Adaptimmune initiates Phase I/IIa open-label clinical trial in patients with ovarian cancer

Ovary removal during hysterectomy protects against future risk of ovarian cancer

Ovary removal during hysterectomy protects against future risk of ovarian cancer

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Verastem's defactinib gets FDA orphan drug designation for treatment of mesothelioma

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Array BioPharma announces positive results from ARRY-502 Phase 2 trial for allergic asthma

Cancer prehabilitation has potential to reduce problems, improve physical and mental health outcomes

Cancer prehabilitation has potential to reduce problems, improve physical and mental health outcomes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.